ValuEngine upgraded shares of DSM (OTCMKTS:RDSMY) from a hold rating to a buy rating in a research report released on Monday, April 2nd.
Separately, Zacks Investment Research raised shares of DSM from a hold rating to a buy rating and set a $27.00 price target on the stock in a research note on Thursday, January 4th.
RDSMY stock traded down $0.51 during mid-day trading on Monday, reaching $26.11. 6,962 shares of the stock traded hands, compared to its average volume of 77,631. DSM has a 52 week low of $17.71 and a 52 week high of $26.90. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.61 and a current ratio of 2.44.
DSM Company Profile
Koninklijke DSM N.V., a science-based company, engages in health, nutrition, and materials businesses worldwide. The company operates through three segments: Nutrition, Materials, and Innovation Center. The Nutrition segment offers nutrients, such as vitamins, carotenoids, nutritional lipids, and other ingredients to feed, food, pharmaceutical, and personal care industries; and food enzymes, cultures, yeast extracts, savory flavors, hydrocolloids, and other specialty ingredients for use in dairy, baking, beverage, and savory applications.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for DSM Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DSM and related companies with MarketBeat.com's FREE daily email newsletter.